Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Stay informed with the latest Agenus Inc (NASDAQ: AGEN) news and developments as this clinical-stage immunology company advances its cancer immunotherapy programs. This page aggregates news coverage related to Agenus's clinical trial progress, partnership announcements, regulatory milestones, and corporate developments.
Agenus operates in the immuno-oncology space, developing checkpoint modulators, therapeutic vaccines, and adjuvants designed to harness the immune system against cancer. News coverage typically focuses on clinical data readouts from ongoing trials, strategic collaborations with pharmaceutical partners, and regulatory interactions across various jurisdictions.
Key news themes for AGEN include updates on the company's combination therapy programs targeting solid tumors, progress with proprietary antibody discovery platforms, and announcements regarding manufacturing partnerships. The company's pursuit of regulatory designations and compassionate use approvals in various markets also generates significant coverage.
Investors and stakeholders monitoring Agenus benefit from tracking news related to clinical trial enrollment, data presentations at medical conferences, and partnership economics. As a clinical-stage company, material developments in any of these areas can significantly impact market perception and stock performance.
This news feed provides real-time aggregation of Agenus-related stories from financial news sources, press releases, and industry publications, enabling stakeholders to maintain current awareness of company developments affecting AGEN stock.
Agenus Inc. (NASDAQ: AGEN) reports promising results for botensilimab/balstilimab in treating microsatellite stable colorectal cancer (MSS CRC), showcasing a 24% overall response rate and a 73% disease control rate from a recent study. The company also initiated a Phase 1 study of AGEN1571 for advanced solid tumors. Financially, Agenus ended Q2 with $238 million in cash and achieved $21 million in revenue, a $10 million increase year-over-year. However, net losses narrowed to $49 million from $84 million in Q2 2021, signaling improved financial management.
Agenus (NASDAQ: AGEN), an immuno-oncology company, will participate virtually in the BTIG Biotechnology Conference and hold one-on-one meetings with investors on August 9, 2022, following its second quarter corporate update. The company focuses on developing therapies that activate the immune system to combat cancer and infections, utilizing a combination of antibody therapeutics, adoptive cell therapies, and adjuvants. Agenus is headquartered in Lexington, MA, and aims to expand access to cancer immunotherapy.
Agenus Inc. (Nasdaq: AGEN) has initiated a Phase 1 study of AGEN1571, a novel anti-ILT2 antibody, in patients with advanced solid tumors. The trial aims to evaluate the safety, tolerability, and pharmacokinetic profiles of AGEN1571, both as a standalone treatment and in combination with botensilimab and balstilimab. Preclinical data suggest AGEN1571's potential to enhance immune responses by modulating tumor-associated macrophages and activating various immune cells. The company believes this therapy may overcome resistance to current PD-1 therapies.
Agenus will release its second quarter 2022 financial results before the market opens on August 9, 2022.
The company will host a conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the conference via the provided dial-in numbers or through a webcast.
Agenus is focused on developing therapies for cancer and infections, leveraging a diverse portfolio of therapeutic approaches.
Agenus (NASDAQ: AGEN) announces Dr. Steven O’Day's participation in a panel discussion on immuno-oncology at William Blair’s Biotech Focus Conference on July 12, 2022, at 4:10 PM EST. The conference will be held from July 12-13, 2022, at The St. Regis New York hotel, where Agenus will also conduct one-on-one investor meetings. Agenus focuses on developing therapies that harness the body's immune system to combat cancer and infections, aiming to expand patient access to cancer immunotherapy through innovative combinations and advanced manufacturing capabilities.
Agenus (NASDAQ: AGEN) has reported promising results from its Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer (MSS CRC). Key findings include a 24% overall response rate and a 73% disease control rate, with 80% of responses ongoing at data cutoff. The combination therapy has shown durability, especially in heavily pre-treated patients. A global Phase 2 study is set to begin this year, building on the strong therapeutic potential demonstrated in cold tumors.
Agenus (NASDAQ: AGEN) announced it will host a hybrid webcast on June 29, 2022, at 10:00 AM EST to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC). This data was presented earlier at the ESMO World Congress in Barcelona. The webcast features speakers including Steven O’Day, M.D., and Dr. Anthony El-Khoueiry, among others. Interested attendees can register through the Investors section of the Agenus website. An archived version will be available post-event.
Agenus (NASDAQ: AGEN) announces that their partner GSK's RSV vaccine candidate has shown significant efficacy in adults aged 60 and older in the AReSVi 006 phase III trial. The primary endpoint was met with no safety concerns. Anticipated global regulatory submissions are set for H2 2022. This vaccine contains QS-21 STIMULON, an adjuvant noted for its effectiveness in vaccines like Shingrix. Additionally, Agenus subsidiary SaponiQx is developing eco-friendly manufacturing processes for QS-21 STIMULON, aiming to support broad vaccine production, including responses to pandemics.
Agenus Inc. (NASDAQ: AGEN) has announced three new clinical collaborations, doubling its partnerships in immuno-oncology. Collaborations involve Targovax, Oxford BioTherapeutics, and Immunogenesis, targeting various cancers with a focus on optimizing immunotherapy combinations. The trials will explore synergistic effects of Agenus' candidates like botensilimab and balstilimab alongside other agents. This strategy aims to enhance treatment efficacy for patients with treatment-resistant solid tumors, leveraging Agenus' manufacturing and scientific capabilities.
Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced that Dr. Garo Armen and Dr. Steven O’Day will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:30 AM EST. The event will take place at the New York Marriott Marquis from June 8-10. One-on-one meetings with investors will also be available. A webcast of the chat can be accessed for 90 days post-event. Agenus focuses on therapies that engage the immune system to combat cancer and infections.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
